ABOUT HEMGENIX

Amount of qualified sufferers: CDEC reviewed the uncertainty in the quantity of clients with moderately extreme to extreme hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some patients who will be labeled as obtaining gentle or moderate sickness can have a intense bleeding phenotype